CRISPR: A Calculated Gamble in the Gene Pool

This stock… it’s been haunting my periphery. A flicker in the data stream. Down 9% this year? A mere flesh wound. A challenge. They just dumped another $585.2 million in convertible notes onto the market. Dilution, they call it. I call it a calculated risk. A desperate lunge for oxygen in a sea of red ink. The sharks are circling, naturally. But sometimes, you gotta feed the sharks to stay ahead.








